NDA 219876 · Chimerix
Modeyso
Dordaviprone Hydrochloride · Oral · Protease Activator
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Aug 6, 2025: To treat diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy
Last checked: Nov 19, 2026Latest source record: Aug 6, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Aug 6, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
2 Phase 3, 3 recruiting
FAERS reports
129
97 serious, 72 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 9, 2026.
MODEYSO is indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). MODEYSO is a protease activator indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. ( 1 ) This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Mechanism: Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP). Dordaviprone also inhibits the dopamine D2 receptor. Diffuse midline gliomas harboring an H3 K27M mutation are associated with the loss of H3 K27 trimethylation. In-vitro, dordaviprone activated the integrated stress response, induced apoptosis, and altered mitochondrial metabolism leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma models. Dordaviprone exhibited antitumor activity in cell-based assays and in vivo models of H3 K27M-mutant diffuse glioma.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 6, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
1 products under this application
- MODEYSO · DORDAVIPRONE HYDROCHLORIDE EQ 125MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dordaviprone" as an intervention, any sponsor and status, largest first.
- ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)Pivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT05580562 · 510 participants (planned) · Start Jan 23, 2023 · Primary completion Jun 2028
Drug: Dordaviprone (ONC201); Dordaviprone (ONC201) + Placebo · For: H3 K27M; Glioma
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 162 sites in all
- Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0Pivotal-lookingRecruiting
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT05476939 · 433 participants (planned) · Start Sep 29, 2022 · Primary completion Sep 2028
Drug: Everolimus; ONC201 · For: Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant; Diffuse Midline Glioma, H3K27-altered
Sites: Brussels, Belgium; Leuven, Belgium; Aarhus, Denmark · 56 sites in all
- ONC201 in Pediatric H3 K27M GliomasTerminated
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT03416530 · 134 participants · Start Jan 25, 2018 · Primary completion Dec 31, 2022
Drug: Dordaviprone (ONC201) · For: Diffuse Intrinsic Pontine Glioma; Glioma, Malignant
Sites: San Francisco, California; Miami, Florida; Atlanta, Georgia · 8 sites in all
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT02525692 · 84 participants · Start Jan 2016 · Primary completion Apr 17, 2023
Drug: Dordaviprone (ONC201) · For: Glioblastoma; Diffuse Midline Glioma; H3 K27M Glioma and 3 more
Sites: Los Angeles, California; Miami, Florida; Boston, Massachusetts · 5 sites in all
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT03295396 · 73 participants · Start Oct 30, 2017 · Primary completion Dec 31, 2022
Drug: Dordaviprone (ONC201) · For: Glioma
Sites: San Francisco, California; Stanford, California; Ann Arbor, Michigan · 9 sites in all
National Cancer Institute (NCI)NIH
NCT05630794 · 36 participants (planned) · Start Oct 6, 2025 · Primary completion Jul 1, 2028
Drug: Dordaviprone Hydrochloride · For: Colorectal Adenomatous Polyp; Colorectal Carcinoma; Familial Adenomatous Polyposis and 1 more
Sites: Ann Arbor, Michigan; St Louis, Missouri; Cleveland, Ohio · 5 sites in all
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT03485729 · 27 participants · Start Mar 21, 2018 · Primary completion Jan 19, 2023
Drug: Dordaviprone (ONC201) · For: Endometrial Cancer Recurrent
Sites: New Brunswick, New Jersey; Chapel Hill, North Carolina; Philadelphia, Pennsylvania
University of NebraskaAcademic, hospital or other
NCT03932643 · 20 participants · Start Jul 30, 2019 · Primary completion Mar 27, 2025
Drug: ONC-201 · For: Acute Myeloid Leukemia; Myelodysplastic Syndromes
Sites: Omaha, Nebraska
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death60
- fatigue15
- disease progression11
- nausea10
- neoplasm progression9
- seizure7
- vomiting7
- constipation6
- hospitalisation6
- off label use6
- product dose omission issue6
- headache5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 30 |
| 2026 | 99 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
Arrillaga-Romany I, Lassman A, McGovern SL, et al. · Neuro Oncol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Odia Y, Koschmann C, Vitanza NA, et al. · Neuro Oncol 2024 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm.
Bhatt VR, Wichman CS, Bouska A, et al. · Am J Hematol 2026 · Clinical Trial, Phase I
- A phase 1, randomized, crossover trial to assess the effect of itraconazole on the pharmacokinetics of dordaviprone in healthy adults.
Faison SL, Batonga J, Arumugham T, et al. · Br J Clin Pharmacol 2025 · Clinical Trial, Phase I, Randomized Controlled Trial
- A Phase 1 Study to Evaluate the Absorption, Metabolism, and Disposition of Dordaviprone in Healthy Adult Participants.
Teffera Y, Tippin T, Bartkus A, et al. · Clin Pharmacol Drug Dev 2025 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of Dordaviprone and the Effects of Food on the Bioavailability of Dordaviprone in Healthy Adult Subjects.
Faison SL, Batonga J, Arumugham T, et al. · Clin Pharmacol Drug Dev 2025 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Chimerix
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.